Your browser doesn't support javascript.
loading
Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study.
Neumann, Frank; Markett, Judith; Fenk, Roland; Pooten, Monika; Koch, Anne; Bruennert, Daniela; Schimkus, Nadine; Wulfert, Michael; Royer-Pokora, Brigitte; Kronenwett, Ralf; Haas, Rainer; Gattermann, Norbert.
Afiliação
  • Neumann F; Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Moorenstr. Duesseldorf, Germany. frank.neumann@med.uni-duesseldorf.de
Hematol Oncol ; 26(4): 213-8, 2008 Dec.
Article em En | MEDLINE | ID: mdl-18449950
This study evaluates response-adapted treatment of chronic myelogenous leukaemia (CML) in chronic phase using molecular response criteria. bcr-abl/G6PDH ratios were assessed by Light-Cycler quantitative real-time polymerase chain reaction (PCR( in 277 peripheral blood samples from 33 patients, before and every 3 months during therapy. Sixty-six per cent (22/33) of the patients fulfiled our molecular response criterion of > or = 1 log decrease in bcr-abl transcript after 6 or > or = 2 log decrease after 9 and every following 3 months. Dose escalation was necessary for 33% (11/33) of the patients. Of these, 54% (6/11) achieved a reduction of bcr-abl mRNA by > or = 2 log (n = 3) or > or = 3 log (n = 3) with 800 mg Imatinib. Forty-five per cent (5/11) showed insufficient molecular response with 800 mg Imatinib and received Nilotinib. In conclusion, the assessment of molecular response permits an individual patient-tailored treatment of CML in first chronic phase, resulting in the majority of patients achieving a major molecular response after 2 years of therapy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Pirimidinas / Antineoplásicos Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2008 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Pirimidinas / Antineoplásicos Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2008 Tipo de documento: Article